If you’ve been living with a diagnosis of PCOS, there’s a big medical update that affects you personally. PCOS has officially been changed to PMOS and this is not a cosmetic change. It’s a clinical correction based on ten years of worldwide research.
On 12 May 2026, the medical condition Polycystic Ovary Syndrome (PCOS) was officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The new terminology was published in The Lancet and endorsed by more than 22,000 medical experts worldwide. Knowing why PCOS changed to PMOS — and what Polyendocrine Metabolic Ovarian Syndrome is really all about — could make a difference in how your condition is diagnosed and treated, especially if you’re a woman in India.
What is PMOS? What is Polyendocrine Metabolic Ovarian Syndrome?
PMOS is Polyendocrine Metabolic Ovarian Syndrome — a name that was carefully chosen as it describes exactly what the condition is: a multi-system hormonal and metabolic disorder, not just an ovarian disorder.
Every word is purposeful:
- Poly-endocrine – Effects involving androgens, insulin and neuroendocrine signals on multiple hormonal pathways
- Metabolic — This is a disorder that is very much related to insulin resistance and general metabolic health, not just reproductive symptoms
- Ovarian – Ovarian function, ovulation and follicle development are still key – but cysts are not defining
- Syndrome – a complex disorder affecting several organ systems at the same time
This name tells doctors and patients something the old name never did: this condition is so much more than the ovaries.
Why PMOS not PCOS? The Problem with the Old Name
Polycystic meant cysts in the ovaries were the cause and the core of the condition. It was never really like that.
Research has repeatedly shown that many women with PCOS do not have ovarian cysts at all. On the other hand, some women have cysts on their ovaries without other symptoms of the syndrome. The term created circular, misleading logic — one that resulted in missed diagnosis, fractured care and needless stigma for women who didn’t fit the “cyst” profile.
The old label also meant doctors concentrated on reproductive symptoms, often missing the hormonal imbalance in women that underpins the condition at its core — insulin resistance, androgen excess and disrupted neuroendocrine signalling.
The Science Behind PCOS Renamed to PMOS
Why Doctors Prefer the Term PMOS
Short answer:
PMOS is better than PCOS because it correctly recognizes the condition as a multi-system hormonal and metabolic disorder, rather than just a problem with ovarian cysts. The old name caused delayed diagnoses and incomplete treatment for millions of women.
The name change was not a re-branding exercise. This was the product of a hard-won science of ten years. More than 14,000 survey responses were collected from patients and healthcare professionals in multiple countries. The final consensus was published in The Lancet and presented at the European Congress of Endocrinology in Prague.
Reasons doctors supported the change include:
- 86% of the patients surveyed and 71% of the clinicians surveyed supported the use of a biologically accurate name
- The old name masked endocrine and metabolic features leading to delayed diagnoses and fragmented care
- PMOS correctly identifies the three main systems involved: hormonal, metabolic and ovarian
“It’s not about ovarian cysts,” says an endocrinologist at NewYork-Presbyterian/Weill Cornell Medical Center. “It’s a complex, multisystem hormonal disorder that affects reproductive health, cardiometabolic risk, mental health, dermatology, and more.”
Insulin Resistance and PMOS Role
Direct Answer:
Insulin resistance is present in an estimated 70-80% of women with PMOS, including those who are not overweight. It is now considered one of the top drivers of the condition, and one of the most treatable.
Here is where the name change has the most practical impact, particularly for women in India.
It is well known that Indian women develop metabolic complications at younger ages and often lower BMI cutoffs compared to Western populations. A woman with a “healthy” BMI can have a lot of visceral fat and insulin resistance – what clinicians call lean PMOS. This profile was often overlooked in the old PCOS paradigm.
India already has a high burden of insulin resistance, prediabetes, dyslipidaemia and cardiovascular risk. By considering PMOS as a metabolic state, testing for insulin resistance becomes a part of the diagnostic process, not an afterthought.
How do we diagnose PMOS?
Direct Answer:
PMOS diagnosis isn’t just an ultrasound. This is irrespective of whether or not there are ovarian cysts. This merits a thorough evaluation of hormonal (androgens, LH, FSH), metabolic (fasting insulin, HOMA-IR, lipid profile) and clinical markers.
The revised diagnostic approach consists of:
| Diagnostic Marker | What it Indicates |
| Fasting insulin + HOMA-IR | Level of insulin resistance |
| Testosterone (total & free) | Androgen excess |
| LH:FSH ratio | Neuroendocrine disruption |
| Lipid profile | Cardiometabolic risk |
| Pelvic ultrasound | Ovarian morphology |
| Thyroid panel | Exclude concurrent thyroid dysfunction |
If your diagnosis of PCOS was based only on ultrasound, then the new PMOS criteria may mean your diagnosis is incomplete.
Can PMOS Influence Fertility?
Direct Answer:
Yes. PMOS disrupts ovulation by androgen excess, insulin resistance and altered LH/FSH signalling. Getting the diagnosis early and right makes a big difference for fertility because it means that treatment can be focused on the hormonal and metabolic factors that are causing the problem.
Insulin resistance interferes with normal ovulation. Androgens prevent the follicles from maturing to high levels.
They’re not just reproductive nuisances – they’re measurable, treatable hormonal disorders.
Women who undergo a comprehensive PMOS assessment, rather than just an ultrasound, are more likely to comprehend the precise factors influencing their fertility and to pursue tailored treatment.
Why the Name Change is Important for Indian Women
India has the highest burden of insulin resistance in the world. Here women present younger with PMOS, have metabolic complications which develop faster and at lower body weights than in Western clinical data.
The transition to PMOS means:
- Metabolic screening no longer rules out lean women
- Doctors are urged to look beyond ovaries to the whole hormone and metabolic system
- Treatment plans can address insulin resistance, androgen excess and cardiovascular risk all together – not as separate issues
- Stigma is lessened when the disorder is described as a complex medical syndrome rather than a lifestyle problem
This is not semantical updating for Indian women.
It is a badly-needed clinical correction.
Summary
PCOS has been renamed PMOS – the new name, Polyendocrine Metabolic Ovarian Syndrome, finally tells the clinical truth about what this condition is.
The old name indicated the cysts.
The new name recognizes a polyendocrine, metabolic, ovarian disorder that requires evaluation and treatment of the whole body.
To know why PCOS changed to PMOS is not only academic. It affects how you are screened, diagnosed and treated – particularly if you are an Indian woman of normal weight with persistent hormonal or metabolic symptoms.
If you have been diagnosed with PCOS – or think you may have PMOS – the next step is a full hormonal and metabolic assessment, not just an ultrasound. Get Diagnosed today
Know more about tests here.
FAQs
What makes PMOS more accurate than PCOS?
PMOS is more accurate as it represents the true nature of the condition, a multi-system disorder involving hormonal, metabolic and ovarian dysfunction. The old name for PCOS was focused on ovarian cysts, which are not present in all patients and are not the main cause of the condition.
Is PMOS same as PCOS?
Yup. PMOS is pretty much the same thing as PCOS, but PCOS was officially renamed to PMOS in May 2026. The idea behind the rename was more about getting the name to match the hormonal plus metabolic complexity of the condition, not to signal some new or completely different illness.
Why was PCOS changed to PMOS?
PCOS changed to PMOS because the old name was clinically misleading.
Not all women with the condition have ovarian cysts and the focus on cysts meant missed diagnoses and incomplete treatment.
The rename was published in The Lancet in May 2026 following a decade-long global consensus process involving more than 22,000 experts.
What is the full form of PMOS?
PMOS stands for Polyendocrine Metabolic Ovarian Syndrome.
The name emphasizes that the disorder involves several endocrine (hormonal) pathways along with metabolic dysfunction — especially insulin resistance — and ovarian abnormalities.
Is PMOS a metabolic disease?
Yes — kind of.
Insulin resistance, dyslipidaemia and increased cardiometabolic risk are hallmarks of PMOS. Hence the term “metabolic” was added to the new name.
Research indicates that 70–80% of women with PMOS, including women with a normal BMI, have insulin resistance.
How do we diagnose PMOS?
Diagnosis of PMOS requires a full assessment of hormonal markers (androgens, LH, FSH), metabolic markers (fasting insulin, HOMA-IR, lipid profile) and clinical evaluation of symptoms.
A complete diagnosis can no longer be made with ultrasound alone.
Can PMOS affect fertility?
Yes. PMOS affects normal follicle development by insulin resistance and excess androgen, which results in disrupted ovulation.
Getting diagnosed early, and correctly, including a metabolic screen, greatly improves a woman’s ability to understand and deal with fertility problems.
